Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhangwei Chen has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Juying Qian

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China

    25 shared publications
  • Junbo Ge

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases

    17 shared publications
  • Danbo Lu

    Department of Cardiology Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine Shanghai China

    11 shared publications
  • Muyin Liu

    Department of Cardiology Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine Shanghai China

    11 shared publications
  • Su Li

    Department of Cardiology Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine Shanghai China

    11 shared publications
  • Ao Chen

    Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China

    10 shared publications

Latest Publications

  • Finerenone Alleviates Cardiac Microvascular Injury and Neutrophil Extracellular Traps Formation in Diabetic Cardiomyopathy via Regulating AKT1 Phosphorylation

    by Su Li, Hexi Zhang, Muyin Liu, Wentao Zhu, Xiaopei Yan, Wenyan Qiu, Yuan Tian, Xiaoyu Lian, Danbo Lu, Zhangwei Chen, et al.

    Background: Diabetes mellitus is commonly featured with cardiac microvascular dysfunction and chronic low‐grade inflammation, contributing to the progression of diabetic cardiomyopathy (DCM). Finerenone confers cardio‐renal protection in diabetic settings, yet its underlying mechanisms remain incompletely defined. Aim: To explore the beneficial effects and molecular mechanisms of finerenone on cardiovascular dysfunction in uncontrolled DCM from the perspectives of neutrophil extracellular traps (NETs) formation and AKT1 phosphorylation. Methods: Finerenone was orally administrated to db/db mice for 24 weeks. Global AKT1 S473A mutation mice and bone marrow chimera mice were subjected to high‐fat diet and streptozotocin‐induced diabetic mouse model. Proteomics, pharmacological network analysis, and cellular thermal shift assay were employed to identify potential molecular targets of finerenone. Multiple approaches, including immunoblotting and immunofluorescence, were used to detect NETs and related cardiac injury. Results: Finerenone treatment significantly improved cardiac and microvascular injury in uncontrolled DCM, as indicated by increased microvascular density, reduced vascular leakage, and alleviated cardiac remodeling. In addition to the mineralocorticoid receptor, AKT1 phosphorylation at S473 was identified as a direct target of finerenone. Finerenone improved AKT1 phosphorylation in endothelial cells to maintain vascular barrier function and reduce damage‐associated molecular patterns (DAMPs) release, thereby suppressing polymorphonuclear (PMN) infiltration and NETosis. In contrast, AKT1 phosphorylation in PMN was suppressed by finerenone for NETs inhibition and related cardiac injuries. Similarly, global and cardiac AKT1 S473A mutation accentuated uncontrolled DCM, whereas myeloid AKT1 S473A mutation improved uncontrolled DCM. Conclusion: Finerenone treatment mitigated microvascular dysfunction, DAMPs release, and NETs‐associated cardiac injury via balancing AKT1 phosphorylation across different cell types, contributing to its cardiovascular protection in uncontrolled DCM.

  • Dynamic Changes and Prognostic Value of Angio-derived Index of Microcirculatory Resistance in Acute Myocardial Infarction: A Cohort Study

    by Jingpu Wang, Wei Gao, Zhe Wang, Fang Zhang, Jianhui Song, Qiyu Zhang, Jinying Zhou, Rende Xu, Leilei Ma, Yan Xia, et al.

  • Open Access

    Ultra-Low-Dose Noise-Free Technology to Reduce Radiation Exposure During Coronary Angiography

    by Jinying Zhou, Qiyu Zhang, Hao Lu, Yizhe Wu, Li Shen, Jianying Ma, Rende Xu, Feng Zhang, Zhangwei Chen, Juying Qian, et al.

    BACKGROUND: Percutaneous coronary intervention (PCI) is a cornerstone treatment for coronary artery disease. As procedural volumes continue to rise, the associated radiation risk from angiography systems has drawn increasing concern. Thus, we developed a novel ultra-low-dose Noise-Free technology to optimize angiography systems. This study aims to investigate whether it effectively reduces radiation exposure in real-world coronary interventions. METHODS: A comparative study on a single-center, real-world, observational cohort. The primary end point was an intergroup comparison of procedural radiation exposure, including dose area product, air kerma, and dose rate, stratified by exposure mode (fluoroscopy or cine) and procedure type (diagnostic coronary angiography, single-vessel PCI, or chronic total occlusion PCI). The secondary end point included an expert semi-quantitative assessment and a quantitative contrast-to-noise ratio for image quality. RESULTS: A total of 380 procedures (102 coronary angiography, 78 single-vessel PCI, and 200 chronic total occlusion PCI) were performed in 380 patients using 4 different angiography systems. There was no significant difference in baseline patient characteristics, procedural time, or operator experience. In coronary angiography procedures, the ultra-low-dose technique demonstrated a total air kerma of 60.3 (38.5–74.1) mGy, total dose area product of 4.0 (2.9–5.2) Gy·cm 2 , fluoroscopy dose rate of 7.9 (6.0–9.6) mGy/min, and cine dose rate of 51.7 (37.4–64.9) mGy/min, corresponding to 40% to 70%, 37% to 66%, 16% to 62%, and 25% to 79% reductions than others, respectively. Similar radiation reductions were observed for single-vessel PCI. For chronic total occlusion PCI, the corresponding percentages of radiation reduction in total air kerma, total dose area product, fluoroscopy dose rate, and cine dose rate were 59% to 73%, 54% to 69%, 22% to 64%, and 60% to 79%, respectively, relative to the other 3 systems. The semi-quantitative assessment and contrast-to-noise ratio analysis showed comparable image quality between the 4 systems. CONCLUSIONS: The Noise-Free technique reduced radiation exposure across cumulative and rate metrics while preserving diagnostic image quality, with the greatest reduction observed in complex cases. These findings support its clinical utility for lowering radiation risk.


  • Open Access

    Heart failure in 2025: new insights, therapies, and clinical directions

    by Zifan Shen, Pingjing Zheng, Gaocheng Gu, Yang Zhang, Zhangwei Chen, Juying Qian

    Heart failure (HF) remains a major cause of morbidity and mortality globally, affecting between 1% and 3% of the total population. Despite the great efficacy of guideline-directed medical therapy (GDMT), patients still face high rates of rehospitalization and mortality. In the past year, emerging research has brought multiple up-to-date insights into HF treatment and substantial new options for clinicians. This review synthesizes landmark research and clinical progress in 2025 concerning epidemiological trends, causes, risk factors and treatments, aiming to update the evolving landscape of HF treatment. Significant progress is noted in pharmacotherapy (e.g., finerenone, tirzepatide) and device-based therapies [e.g., preCARDIA, cardiac resynchronization therapy with defibrillator (CRT-D)]. The completion of large-scale clinical trials, such as the DAPA ACT HF-TIMI 68 trial and the VICTOR trial, has offered solid evidence for the evolution in clinical practice. The emergence of novel devices offers promising alternatives and supplements to conventional therapies as well. Additionally, cutting-edge therapies like stem cell therapy have also revealed promising clinical prospects. Despite continuous therapeutic advances, substantial unmet needs in treatment and management still present a great challenge, necessitating further research to discover novel and better therapeutic strategies. Hence, major large-scale clinical trials initiated in 2025 are synthesized and anticipated as well. In brief, this review provides a timely update to guide clinical practice and future investigation.


  • Open Access

    Comparison of Flow Ratio Derived From IVUS With CAG in Complex Lesions

    by Rende Xu, Zhe Wang, Congcong Pan, Wei Gao, Leilei Ma, Yizhe Wu, Zhangwei Chen, Yang Lu, Yong Dong, Wei Yu, et al.


  • Open Access

    Periprocedural Assessment of Coronary Microcirculatory Function to Predict Clinical Outcomes After Elective Percutaneous Coronary Intervention

    by ChenGuang Li, You Zhou, Danbo Lu, Jiaqi Ma, Chunfeng Dai, Jianying Ma, Yumeng Hu, Jianyi Xu, Jianping Xiang, Zhangwei Chen, et al.

    Background: Percutaneous coronary intervention (PCI) could restore epicardial blood flow through the stent‐based angioplasty. However, coronary microcirculatory function also affects clinical outcomes and can be quantified by the angiography‐derived index of microcirculatory resistance (angio‐IMR). The prognostic significance of periprocedural angio‐IMR in patients undergoing elective PCI remains unclear. This study aimed to assess angio‐IMR before and after PCI, as well as their association with long‐term prognosis. Methods: Data from 1768 patients with stable coronary artery disease undergoing elective PCI were analyzed. The primary end point was major adverse cardiac events (MACE) comprising death and nonfatal myocardial infarction. Results: The median angio‐IMR was 11.3 (interquartile range, 7.7–15.0) and 17.0 (interquartile range, 14.1–20.4) before and after PCI ( P 10 was independently associated with an increased risk of MACE (adjusted hazard ratio, 2.43 [95% CI, 1.32–4.49]; P =0.004). In comparison with periprocedural myocardial infarction, Δangio‐IMR>10 could provide additional prognostic value in predicting MACE (area under the curve, 0.681 versus 0.635, P <0.05). Conclusions: Δangio‐IMR was a predictor of MACE in patients with stable coronary artery disease undergoing elective PCI. Incorporating Δangio‐IMR could enhance the identification of patients at high risk of MACE.


  • Open Access

    Prognostic Value of Functional Incomplete Revascularization in Patients Undergoing Valve Surgery With Coronary Artery Disease

    by Fang Zhang, Wei Gao, Wenshuo Wang, Runda Wu, Yan Xia, Jingpu Wang, Qiyu Zhang, Jinying Zhou, Rende Xu, Zhangwei Chen, et al.


  • Top Cited Papers

    GUCY1A1-LDHA Axis Suppresses Ferroptosis in Cardiac Ischemia-Reperfusion Injury

    by Ming Yin, Su Li, Muyin Liu, Wentao Zhu, Yuqiong Chen, Wenyan Qiu, Qiyu Li, Youran Li, Jinxiang Chen, You Zhou, et al.

    BACKGROUND: Ischemia-reperfusion injury compromises revascularization strategies for myocardial infarction and contributes to cardiac microvascular disorders. This study aimed to investigate the role of the sGC (soluble guanylate cyclase)–cGMP–PKG (protein kinase G) pathway in cardiac microvascular reperfusion injury with a focus on ferroptosis. METHODS: Key genes in the sGC-cGMP-PKG pathway were analyzed at different reperfusion times using bulk and single-cell mRNA sequencing. Endothelial cell (EC) specific conditional GUCY1A1 (guanylate cyclase soluble subunit alpha 1) knockout mice (GUCY1A1 flox/flox /-CreERT2) and adeno-associated virus transfer-induced EC-specific GUCY1A1-overexpressing mice were assessed for cardiac microvascular reperfusion injury. LDHA (lactate dehydrogenase A) and GPX4 (glutathione peroxidase 4) phosphorylation sites were identified by mass spectrometry and mutationally inactivated via the CRISPR–Cas9 (clustered regularly interspaced short palindromic repeats and their associated protein 9) system. Protein interactions and chaperone-mediated autophagy of GPX4 were detected using coimmunoprecipitation assays. RESULTS: GUCY1A1 was decreased in the EC group after cardiac ischemia-reperfusion injury. EC-specific knockout of GUCY1A1 further reduced microvascular perfusion, increased the no-reflow area, and enlarged the infarction area in the acute phase of ischemia-reperfusion injury, ultimately aggravating cardiac dysfunction and structural remodeling in the chronic phase. In contrast, GUCY1A1 overexpression or its activator, vericiguat, alleviated microvascular dysfunction via the suppression of endothelial ferroptosis; the effects were majorly dependent on PKG activity. Mechanistically, PKG phosphorylated LDHA at threonine 95 and activated the LDHA moonlighting kinase function to phosphorylate GPX4, resulting in reduced chaperone-mediated autophagy-dependent degradation of GPX4 and ferroptosis. In human ischemic cardiomyopathy, GUCY1A1 expression, LDHA phosphorylation at threonine 95, and GPX4 phosphorylation at serine 131 were negatively associated with lipid peroxidation and cardiac fibrosis, suggesting that this pathway was involved in the pathogenesis of cardiac ischemia-reperfusion injury. CONCLUSIONS: These findings indicate that the compromise of the sGC-cGMP-PKG pathway is associated with reduced phosphorylation of LDHA and GPX4, and that GUCY1A1 activation may be considered as a strategy to alleviate endothelial ferroptosis and cardiac microvascular reperfusion injury.


  • Open Access

    Clinical factors associated with severe coronary stenosis in patients undergoing cardiac surgery

    by Rui Wang, Wei Gao, Xinyu Che, Ruopei Shen, Chunfeng Dai, Yan Xia, Ao Chen, Danbo Lu, Jiaqi Ma, Hungju Chen, et al.

    Many cardiovascular patients undergoing valve surgeries require coronary angiography (CAG). Positive results may lead to bypass surgery, while negative results require no treatment. Although informative, CAG is costly and exposes patients to significant radiation. This study aimed to develop a model to reduce unnecessary procedures. A retrospective cohort study was conducted on 5,086 patients who underwent valve repair/replacement or other cardiac surgeries at Zhongshan Hospital between 2016 and 2021 and received CAG. Patients treated between 2016 and 2020 formed the training set, while those treated in 2021 constituted the validation set. Severe coronary stenosis was defined as a ≥ 50% reduction in luminal diameter. Logistic regression analysis identified independent predictors in the training set, and a scoring system (Coronary Angiography Positivity Prediction Score) was constructed based on the β-coefficients of each variable. The model was evaluated for discrimination and calibration. Among 4,049 patients, 536 (13.2%) had severe coronary stenosis. Independent predictors included age ≥ 60 years, male sex, hypertension, diabetes, hyperlipidemia, and left ventricular ejection fraction ≤ 58%. The scoring system ranged from 0 to 11 points and demonstrated good discrimination, with an area under the receiver operating characteristic curve of 0.715 (95% confidence interval: 0.694–0.740) in the training set. In the high-risk group (≥ 6 points), the probability of severe coronary stenosis was 23.1%, compared to 8% in the low-risk group (< 6 points). The scoring system also performed well in the validation set with the curve of 0.740 (95% CI, 0.695–0.784). We developed and validated a scoring system based on six clinical variables to predict severe coronary stenosis in patients undergoing valve surgeries. This tool may help optimize individual treatment strategies and reduce unnecessary CAG procedures.